Últimas noticias sobre Cardiff Oncology (NASDAQ:CRDF) Bolsa

CARDIFF ONCOLOGY INC

Cardiff Oncology

Cardiff Oncology Inc is a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with the greatest unmet medical need. It is focusing on clinical programs in indications such as RAS-mutated metastatic colorectal cancer ("mCRC"), as well as in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma ("mPDAC"), small cell lung cancer ("SCLC"), and triple negative breast cancer ("TNBC"). Geographically, the company only operates in the United States.

Cardiff Oncology Inc

Editor's Note: This headline and story have been updated to clarify that the FDA approval was for an expanded indication to treat acute HCV.
The U.S. Food and Drug Administration (FDA) approved a label expansion for AbbVie Inc's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>) Mavyret (glecaprevir/pibrentasvir) to include treatment of acute hepatitis C virus (HCV) infection in patients without cirrhosis <a href="https://www.benzinga.com/general/health-care">or with compensated cirrhosis.</a>
Glecaprevir, one of the two DAAs in Mavyret, was Discovered by Enanta Pharmaceuticals, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENTA#NASDAQ">ENTA</a>) and developed and commercialized by AbbVie.
Also Read: <a href="https://www.benzinga.com/25/05/45621885/abbvie-highlights-cancer-trial-data-presentation-at-upcoming-asco-annual-meeting" target="_blank" rel="noreferrer noopener">AbbVie To Present Cancer Trial Data At Upcoming ASCO Event</a>
With this approval, Mavyret is the first and only DAA therapy approved to treat patients with acute HCV in eight weeks with a 96% cure rate.
HCV is a highly infectious blood-borne <a target="_blank" href="https://www.benzinga.com/pressreleases/25/06/n45889177/u-s-fda-approves-expanded-indication-for-abbvies-mavyret-glecaprevirpibrentasvir-as-first-and-only" rel="noreferrer noopener">disease affecting the liver</a>.
The United States&nbsp;is expected to incur&nbsp;around $120 billion&nbsp;in total medical costs over the next 10 years through 2035 linked to chronic liver disease and other related conditions caused by untreated HCV.
Data from the Phase 3, multicenter, single-arm prospective study evaluating the safety and efficacy of Mavyret eight-week treatment in adults with acute HCV infection supported the label expansion.
The study results showed Mavyret to be a highly efficacious treatment for people with acute HCV.
The majority of the adverse events reported were mild or moderate in severity. Fatigue, asthenia, headache, and diarrhea were the most common adverse events.
In 2017, the FDA approved Mavyret to <a target="_blank" href="https://news.abbvie.com/2019-09-26-AbbVie-Receives-FDA-Approval-of-MAVYRET-R-glecaprevir-pibrentasvir-to-Shorten-Treatment-Duration-to-Eight-Weeks-for-Treatment-Naive-Patients-with-Chronic-Hepatitis-C-and-Compensated-Cirrhosis-Across-All-Genotypes" rel="noreferrer noopener">treat</a> adults with chronic (lasting a long time) hepatitis C virus (hep C) genotypes 1, 2, 3, 4, 5, or 6 infections without cirrhosis or with compensated cirrhosis.
In 2019, the FDA approved Mavyret to shorten the once-daily treatment duration from 12 to 8 weeks in treatment-naïve, compensated cirrhotic, chronic hepatitis C (HCV) patients across all genotypes (GT1-6).
Price Action: ABBV stock is trading higher by 1.54% to $192.43 at last check Wednesday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/general/biotech/25/03/44202109/atea-pharma-cuts-workforce-by-25-expects-15-million-in-cost-savings-plans-phase-3-hepatitis-c-trial" target="_blank" rel="noreferrer noopener">Atea Pharma Cuts Workforce By 25%, Expects $15 Million In Cost Savings, Plans Phase 3 Hepatitis C Trial</a></li>
</ul>
Photo by Tada Images via Shutterstock

Biotech

Large Cap

News

Health Care

General

ABBV

ENTA

FDA Expands AbbVie's Mavyret Label To Include Acute Hepatitis C Treatment (CORRECTED)

<h3>Gainers</h3>
<ul>
<li>Applied Optoelectronics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAOI#NASDAQ">AAOI</a>) shares moved upwards by 14.4% to $18.67 during Wednesday's after-market session. The market value of their outstanding shares is at $1.0 billion. </li>
<li>FOXO Technologies (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/FOXO#AMEX">FOXO</a>) shares increased by 12.21% to $0.34. The company's market cap stands at $2.2 million. </li>
<li>Argo Blockchain (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARBK#NASDAQ">ARBK</a>) stock rose 7.31% to $0.42. The market value of their outstanding shares is at $26.7 million. </li>
<li>Oracle (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ORCL#NYSE">ORCL</a>) shares increased by 6.78% to $188.34. The market value of their outstanding shares is at $528.1 billion. As per the press release, Q4 earnings came out today. </li>
<li>Oblong (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OBLG#NASDAQ">OBLG</a>) shares increased by 6.37% to $4.3. The market value of their outstanding shares is at $5.6 million. </li>
<li>QuickLogic (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QUIK#NASDAQ">QUIK</a>) shares rose 5.25% to $6.41. The market value of their outstanding shares is at $101.5 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Castellum (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/CTM#AMEX">CTM</a>) shares fell 13.2% to $1.19 during Wednesday's after-market session. The company's market cap stands at $102.3 million. </li>
<li>Karooooo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KARO#NASDAQ">KARO</a>) stock declined by 10.97% to $53.0. The market value of their outstanding shares is at $1.6 billion. </li>
<li>FiEE (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MINM#NASDAQ">MINM</a>) shares fell 4.32% to $3.07. The company's market cap stands at $22.5 million. </li>
<li>Alpha Modus Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMOD#NASDAQ">AMOD</a>) shares decreased by 3.45% to $1.12. The company's market cap stands at $15.4 million. </li>
<li>Sonim Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SONM#NASDAQ">SONM</a>) stock fell 3.29% to $1.1. The market value of their outstanding shares is at $11.3 million. 
See Also: <a href="http://www.benzinga.com/money/tech-stocks/" title="www.benzinga.com/money/tech-stocks/">www.benzinga.com/money/tech-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

AAOI

AMOD

ARBK

FOXO

KARO

MINM

OBLG

ORCL

QUIK

SONM

11 Information Technology Stocks Moving In Wednesday's After-Market Session

<h3>Gainers</h3>
<ul>
<li>ZHONGCHAO (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZCMD#NASDAQ">ZCMD</a>) shares rose 10.6% to $1.15 during Wednesday's after-market session. The market value of their outstanding shares is at $28.9 million. </li>
<li>Greenlane Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GNLN#NASDAQ">GNLN</a>) stock increased by 6.66% to $0.01. The company's market cap stands at $8.1 million. </li>
<li>Dana (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DAN#NYSE">DAN</a>) stock rose 5.87% to $18.75. The company's market cap stands at $2.7 billion. </li>
<li>Beachbody Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BODI#NYSE">BODI</a>) shares moved upwards by 5.59% to $4.15. The company's market cap stands at $29.0 million. </li>
<li>Naas Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NAAS#NASDAQ">NAAS</a>) stock moved upwards by 5.57% to $1.32. The company's market cap stands at $18.1 million. </li>
<li>Leslies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LESL#NASDAQ">LESL</a>) shares moved upwards by 4.99% to $0.66. The company's market cap stands at $121.5 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Oxford Industries (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OXM#NYSE">OXM</a>) stock declined by 12.1% to $44.0 during Wednesday's after-market session. The company's market cap stands at $690.8 million. As per the news, the Q1 earnings report came out today. </li>
<li>GameStop (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GME#NYSE">GME</a>) shares fell 10.16% to $25.65. The company's market cap stands at $11.4 billion. The company's, Q1 earnings came out yesterday. </li>
<li>Mixed Martial Arts Group (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/MMA#AMEX">MMA</a>) shares fell 7.02% to $1.06. The company's market cap stands at $11.1 million. </li>
<li>Jiuzi Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JZXN#NASDAQ">JZXN</a>) shares fell 5.85% to $2.72. The market value of their outstanding shares is at $29.9 million. </li>
<li>Jiade (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JDZG#NASDAQ">JDZG</a>) stock decreased by 5.83% to $0.28. The market value of their outstanding shares is at $6.9 million. </li>
<li>INNEOVA Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INEO#NASDAQ">INEO</a>) stock declined by 5.62% to $1.68. The company's market cap stands at $16.5 million. 
See Also: <a href="http://www.benzinga.com/money/best-consumer-cyclical-stocks/" title="www.benzinga.com/money/best-consumer-cyclical-stocks/">www.benzinga.com/money/best-consumer-cyclical-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

The Beachbody Company, Inc. Class A Common Stock

BODI

GNLN

INEO

JDZG

JZXN

LESL

NAAS

ZCMD

12 Consumer Discretionary Stocks Moving In Wednesday's After-Market Session

<h3>Gainers</h3>
<ul>
<li>Equillium (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EQ#NASDAQ">EQ</a>) shares rose 36.0% to $0.53 during Wednesday's after-market session. The company's market cap stands at $18.7 million. </li>
<li>Healthcare Triangle (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HCTI#NASDAQ">HCTI</a>) shares rose 30.43% to $0.01. The market value of their outstanding shares is at $4.9 million. </li>
<li>Liminatus Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LIMN#NASDAQ">LIMN</a>) stock increased by 17.01% to $13.0. The market value of their outstanding shares is at $338.1 million. </li>
<li>Journey Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DERM#NASDAQ">DERM</a>) shares rose 8.53% to $7.5. The market value of their outstanding shares is at $174.7 million. </li>
<li>Camp4 Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAMP#NASDAQ">CAMP</a>) shares moved upwards by 7.27% to $1.77. The market value of their outstanding shares is at $35.6 million. </li>
<li>Scilex Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SCLX#NASDAQ">SCLX</a>) shares moved upwards by 6.79% to $5.97. The company's market cap stands at $32.7 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Helius Medical Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HSDT#NASDAQ">HSDT</a>) stock declined by 53.4% to $0.52 during Wednesday's after-market session. </li>
<li>Intensity Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTS#NASDAQ">INTS</a>) shares declined by 27.48% to $0.42. The company's market cap stands at $7.7 million. </li>
<li>Jupiter Neurosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JUNS#NASDAQ">JUNS</a>) shares fell 24.13% to $1.51. The market value of their outstanding shares is at $49.9 million. </li>
<li>Catheter Precision (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/VTAK#AMEX">VTAK</a>) shares fell 17.85% to $0.49. The market value of their outstanding shares is at $5.4 million. </li>
<li>Simulations Plus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLP#NASDAQ">SLP</a>) shares declined by 13.02% to $23.0. The market value of their outstanding shares is at $462.5 million. </li>
<li>Nuwellis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NUWE#NASDAQ">NUWE</a>) stock declined by 10.28% to $0.33. The market value of their outstanding shares is at $1.4 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CAMP

DERM

HCTI

HSDT

INTS

JUNS

LIMN

NUWE

SCLX

VTAK

12 Health Care Stocks Moving In Wednesday's After-Market Session

<h3>Gainers</h3>
<ul>
<li>Graphjet Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GTI#NASDAQ">GTI</a>) shares rose 14.0% to $0.07 during Wednesday's after-market session. The company's market cap stands at $10.8 million. </li>
<li>Eve Holding (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EVEX#NYSE">EVEX</a>) stock moved upwards by 5.42% to $5.83. The market value of their outstanding shares is at $1.7 billion. </li>
<li>Solidion Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STI#NASDAQ">STI</a>) stock increased by 4.93% to $3.4. The company's market cap stands at $9.2 million. </li>
<li>Addentax Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATXG#NASDAQ">ATXG</a>) stock moved upwards by 4.66% to $0.74. The market value of their outstanding shares is at $4.4 million. </li>
<li>Aqua Metals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AQMS#NASDAQ">AQMS</a>) shares rose 4.38% to $0.95. The company's market cap stands at $8.4 million. </li>
<li>SUNation Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SUNE#NASDAQ">SUNE</a>) shares increased by 3.63% to $1.71. The company's market cap stands at $5.8 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Dragonfly Energy Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DFLI#NASDAQ">DFLI</a>) shares decreased by 16.7% to $0.33 during Wednesday's after-market session. The company's market cap stands at $3.1 million. </li>
<li>Stem (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STEM#NYSE">STEM</a>) stock decreased by 14.37% to $0.52. The company's market cap stands at $86.0 million. </li>
<li>PS International Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PSIG#NASDAQ">PSIG</a>) shares decreased by 8.7% to $0.38. The market value of their outstanding shares is at $9.9 million. </li>
<li>Northann (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/NCL#AMEX">NCL</a>) stock decreased by 6.83% to $0.25. The company's market cap stands at $13.6 million. </li>
<li>WANG &amp; LEE Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WLGS#NASDAQ">WLGS</a>) shares declined by 6.01% to $0.08. The market value of their outstanding shares is at $1.7 million. </li>
<li>Singularity Future Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SGLY#NASDAQ">SGLY</a>) shares declined by 5.34% to $1.05. The company's market cap stands at $4.4 million. 
See Also: <a href="http://www.benzinga.com/money/best-industrials-stocks/" title="www.benzinga.com/money/best-industrials-stocks/">www.benzinga.com/money/best-industrials-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AQMS

ATXG

DFLI

EVEX

Nuveen Insured California Premium Fund Ii

PSIG

SGLY

STEM

SUNE

WLGS

12 Industrials Stocks Moving In Wednesday's After-Market Session

<a href="https://www.businessinsider.com/microsoft-prepping-ai-copilot-pentagon-2025-6">https://www.businessinsider.com/microsoft-prepping-ai-copilot-pentagon-2025-6</a>

MSFT

'Microsoft is prepping an AI Copilot for the Pentagon'- Business Insider

Verisk Analytics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRSK#NASDAQ">VRSK</a>) has outperformed the market over the past 15 years by 4.95% on an annualized basis producing an average annual return of 16.79%. Currently, Verisk Analytics has a market capitalization of $43.57 billion. 
Buying $1000 In VRSK: If an investor had bought $1000 of VRSK stock 15 years ago, it would be worth $10,307.41 today based on a price of $311.49 for VRSK at the time of writing.
<h3>Verisk Analytics's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1749675720_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

VRSK

$1000 Invested In This Stock 15 Years Ago Would Be Worth This Much Today

Ratings for Penske Automotive Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PAG#NYSE">PAG</a>) were provided by 5 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated Penske Automotive Group and provided 12-month price targets. The average target is $160.0, accompanied by a high estimate of $195.00 and a low estimate of $140.00. Marking an increase of 1.59%, the current average surpasses the previous average price target of $157.50. 
<img src="https://www.benzinga.com/files/images/story/2025/1749675618_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
A comprehensive examination of how financial experts perceive Penske Automotive Group is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jeff Lick</td>
<td>Stephens &amp; Co.</td>
<td>Maintains</td>
<td>Equal-Weight</td>
<td>$140.00</td>
<td>$140.00</td>
</tr>
<tr>
<td>Michael Ward</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$195.00</td>
<td>$185.00</td>
</tr>
<tr>
<td>Jeff Lick</td>
<td>Stephens &amp; Co.</td>
<td>Maintains</td>
<td>Equal-Weight</td>
<td>$140.00</td>
<td>$140.00</td>
</tr>
<tr>
<td>Michael Ward</td>
<td>Citigroup</td>
<td>Announces</td>
<td>Buy</td>
<td>$185.00</td>
<td>-</td>
</tr>
<tr>
<td>Rajat Gupta</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Underweight</td>
<td>$140.00</td>
<td>$165.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Penske Automotive Group. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Penske Automotive Group compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Penske Automotive Group's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Penske Automotive Group's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/PAG/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Penske Automotive Group analyst ratings.</a>
<h2>Discovering Penske Automotive Group: A Closer Look</h2>
Penske Automotive Group operates in 19 US states and overseas. It has over 150 US and Puerto Rico light-vehicle stores as well as 210 franchised dealerships overseas, primarily in the United Kingdom but also in Australia, Germany, Italy, and Japan. The company is the third-largest US publicly traded dealership in terms of light-vehicle revenue and sells more than 40 brands, with over 90% of retail automotive revenue coming from luxury and import names. Other segments are service and finance and insurance. The firm's Premier Truck Group owns 45 truck dealerships selling mostly Freightliner and Western Star brands, and Penske owns 16 used-vehicle stores, mostly in the US and UK under the CarShop (US) and Sytner Select (UK) brands. Penske is based in Bloomfield Hills, Michigan.
<h3>Penske Automotive Group: Delving into Financials</h3>
Market Capitalization: Positioned above industry average, the company's market capitalization underscores its superiority in size, indicative of a strong market presence.
Revenue Growth: Penske Automotive Group's remarkable performance in 3M is evident. As of 31 March, 2025, the company achieved an impressive revenue growth rate of 2.1%. This signifies a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Consumer Discretionary sector.
Net Margin: Penske Automotive Group's net margin is impressive, surpassing industry averages. With a net margin of 3.21%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): Penske Automotive Group's ROE excels beyond industry benchmarks, reaching 4.61%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): Penske Automotive Group's ROA excels beyond industry benchmarks, reaching 1.45%. This signifies efficient management of assets and strong financial health.
Debt Management: With a below-average debt-to-equity ratio of 1.5, Penske Automotive Group adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>Analyst Ratings: Simplified</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

Penske Automotive Group Stock: A Deep Dive Into Analyst Perspectives (5 Ratings)

Offerings

Macy's Files For Mixed Shelf; Size Not Disclosed

In the current market session, PayPal Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PYPL#NASDAQ">PYPL</a>) stock price is at $74.51, after a 0.33% decrease. However, over the past month, the company's stock went up by 2.66%, and in the past year, by 21.24%. Shareholders might be interested in knowing whether the stock is overvalued, even if the company is not performing up to par in the current session. 

<img src="https://www.benzinga.com/files/images/story/2025/1749675616_0.png" alt="Past Year Chart" />

<h3>PayPal Holdings P/E Ratio Analysis in Relation to Industry Peers</h3>
The P/E ratio is used by long-term shareholders to assess the company's market performance against aggregate market data, historical earnings, and the industry at large. A lower P/E could indicate that shareholders do not expect the stock to perform better in the future or it could mean that the company is undervalued. 
Compared to the aggregate P/E ratio of the 35.74 in the Financial Services industry, PayPal Holdings Inc. has a lower P/E ratio of 16.8. Shareholders might be inclined to think that the stock might perform worse than it's industry peers. It's also possible that the stock is undervalued. 

<img src="https://www.benzinga.com/files/images/story/2025/1749675616_1.png" alt="Guage" />

In summary, while the price-to-earnings ratio is a valuable tool for investors to evaluate a company's market performance, it should be used with caution. A low P/E ratio can be an indication of undervaluation, but it can also suggest weak growth prospects or financial instability. Moreover, the P/E ratio is just one of many metrics that investors should consider when making investment decisions, and it should be evaluated alongside other financial ratios, industry trends, and qualitative factors. By taking a comprehensive approach to analyzing a company's financial health, investors can make well-informed decisions that are more likely to lead to successful outcomes.

Intraday Update

Markets

PYPL

A Look Into PayPal Holdings Inc's Price Over Earnings

PPTA

Trading Halt: Halt status updated at 5:00:00 PM ET: Quotation Resumption: News and Resumption Times

WIIM

OKLO

OKLO stock has given up its prior loss. Oklo shares were trading lower after the company announced a $400 million public offering of common stock.

Applied Optoelectronics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAOI#NASDAQ">AAOI</a>) shares climbed in Wednesday's extended trading after the company announced its first volume shipment of high-speed data center transceivers to a major hyperscale <a href="https://www.benzinga.com/pressreleases/25/06/g45892788/applied-optoelectronics-announces-first-volume-shipment-of-data-center-transceivers-to-recently-en">data center customer.</a>
What To Know: Applied Optoelectronics did not name the customer, but said that the hyperscaler had been "recently re-engaged."&nbsp;
Read Next: <a href="https://www.benzinga.com/markets/tech/25/06/45885805/nvidias-jensen-huang-sparks-quantum-stock-frenzy?utm_source=articleShare">Nvidia&#8217;s Jensen Huang Sparks Quantum Stock Frenzy</a>
The company also said this shipment marked the first volume shipment of the advanced high-speed data center transceivers to this customer, as well as the first shipment of significant quantity to this customer in several years.
&#8220;Throughout the year, we have been expecting growth in data center transceiver sales, particularly in the second half of the year,&#8221; commented Dr. Thompson Lin, AOI&#8217;s CEO.&nbsp;
"This first volume shipment to this customer represents a significant milestone on a journey to what we continue to expect to be significant business opportunities with this newly re-engaged customer. As we execute on our previously announced U.S.-based capacity expansion plan, we continue to expect shipments to this customer and other customers to increase in line with our previous commentary of a second-half ramp,&#8221; Dr. Lin added. 
AAOI Price Action: Applied Optoelectronics shares were up 16.23% at $18.97 in Wednesday's extended trading, according to <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>.  
Read Next:&nbsp;
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/movers/25/06/45851086/these-are-the-3-hottest-stock-market-themes-trending-now?utm_source=articleShare">These Are The 3 Hottest Stock Market Themes Trending Now</a></li>
</ul>
Image: Shutterstock

Mid Cap

After-Hours Center

Tech

What's Going On With Applied Optoelectronics Stock?

GameStop Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GME#NYSE">GME</a>) shares are falling in Wednesday&#8217;s after-hours session after the company announced a <a href="https://www.benzinga.com/pressreleases/25/06/b45892533/gamestop-announces-proposed-private-offering-of-1-75-billion-of-convertible-senior-notes">proposed private offering</a>. 
What Happened: After the market close, GameStop announced plans to offer&nbsp;$1.75 billion of&nbsp;0.00%&nbsp;Convertible Senior Notes due 2032&nbsp;to institutional buyers. The company expects to grant the initial purchasers a 13-day option to purchase up to an additional $250 million of the notes. 
GameStop intends to use the net proceeds from the offering to make investments consistent with the company&#8217;s investment policy, as well as for potential acquisitions. 
The offering comes a day after GameStop reported <a href="https://www.benzinga.com/markets/earnings/25/06/45872536/gamestop-q1-earnings-revenue-misses-despite-collectibles-growth-eps-beats-retailer-adds-4710-bitcoin">first-quarter results</a> with revenue of $732.4 million coming in below analyst estimates&nbsp;of $754.24 million, and adjusted earnings per share totaling 17 cents, above estimates of four cents.
GameStop ended the period with approximately $6.4 billion in cash, cash equivalents and marketable securities, but said it used cash to purchase 4,710 Bitcoin&nbsp;subsequent to quarter&#8217;s end.
GME Price Action: <a href="http://benzinga.com/quote/gme" target="_blank" rel="noreferrer noopener">GameStop shares</a> were down 10.02% in after-hours, trading at $25.69 at the time of publication on Wednesday, according to<a href="http://pro.benzinga.com"> Benzinga Pro</a>. GameStop shares are down about 8% year-to-date.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst-color/25/06/45888497/bitcoin-probably-wont-fix-gamestops-troubles">GameStop Video Game Business Has &#8216;No Potential For A Rebound&#8217;: Analyst Says Bitcoin Investment Not Enough</a></li>
</ul>
Image: Jillian Cain Photography/Shutterstock.

Gaming

GameStop Stock Is Tumbling After Hours: Here's Why

AXTI

Beijing Tongmei Xtal Technology Co., A Subsidiary Of AXT, Receives Export Permits For Indium Phosphide From China

HubSpot (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUBS#NYSE">HUBS</a>) has outperformed the market over the past 5 years by 7.72% on an annualized basis producing an average annual return of 21.68%. Currently, HubSpot has a market capitalization of $30.25 billion. 
Buying $100 In HUBS: If an investor had bought $100 of HUBS stock 5 years ago, it would be worth $274.65 today based on a price of $573.60 for HUBS at the time of writing.
<h3>HubSpot's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1749674713_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

HUBS

$100 Invested In HubSpot 5 Years Ago Would Be Worth This Much Today

Oracle Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ORCL#NYSE">ORCL</a>) released its financial results for the fourth quarter of fiscal 2025 after the market close on Wednesday. Here&#8217;s a rundown of the <a href="https://www.benzinga.com/pressreleases/25/06/n45892541/oracle-announces-fiscal-2025-fourth-quarter-and-fiscal-full-year-financial-results">tech giant&#8217;s report</a>.
Q4 Earnings: Oracle reported fourth-quarter revenue of $15.9 billion, beating analyst <a href="http://benzinga.com/quote/orcl/earnings" target="_blank" rel="noreferrer noopener">estimates</a>&nbsp;of $15.58 billion. The company reported fourth-quarter adjusted earnings of $1.70 per share, beating analyst estimates of $1.64 per share, according to <a href="http://pro.benzinga.com/" target="_blank" rel="noreferrer noopener">Benzinga Pro</a>.
Total revenue was up 11% on a year-over-year basis. Here&#8217;s a breakdown of revenue by segment:
<ul class="wp-block-list">
<li>Cloud: $6.7 billion, up 27%</li>
</ul>
<ul class="wp-block-list">
<li>Cloud Infrastructure: $3 billion, up 52%</li>
</ul>
<ul class="wp-block-list">
<li>Cloud Application: $3.7 billion, up 12%</li>
</ul>
<ul class="wp-block-list">
<li>Fusion Cloud ERP: $1 billion, up 22%</li>
</ul>
<ul class="wp-block-list">
<li>NetSuite Cloud ERP: $1 billion, up 18%</li>
</ul>
Oracle noted that its MultiCloud database revenue from Amazon, Google and Azure grew 115% quarter-over-quarter. Remaining performance obligations totaled $138 billion at the end of the quarter, up 41% year-over-year. 
Oracle ended the period with approximately $10.79 billion in cash and cash equivalents.
&#8220;FY25 was a very good year — but we believe FY26 will be even better as our revenue growth rates will be dramatically higher,&#8221; said&nbsp;Safra Catz, CEO of Oracle.
&#8220;We expect our total cloud growth rate — applications plus infrastructure — will increase from&nbsp;24%&nbsp;in FY25 to over&nbsp;40%&nbsp;in FY26. Cloud Infrastructure growth rate is expected to increase from&nbsp;50%&nbsp;in FY25 to over&nbsp;70%&nbsp;in FY26. And RPO is likely to grow more than&nbsp;100%&nbsp;in FY26.&#8221;
Oracle said it expects to continue to see triple-digit MultiCloud revenue growth in fiscal 2026. The company currently has 23 MultiCloud data centers in operation and 47 more are expected to be built over the next 12 months. Oracle also has 29 Cloud@Customer dedicated data centers live with another 30 expected to be built in fiscal 2026.
Oracle Cloud Infrastructure&nbsp;(OCI) consumption revenue grew 62% in the fourth quarter. 
&#8220;We expect OCI consumption revenue to grow even faster in FY26. OCI revenue growth rates are skyrocketing — so is demand,&#8221; said Larry Ellison, chairman and CTO of Oracle.
Oracle&#8217;s board declared a quarterly cash dividend of 50 cents per share, payable on July 24 to shareholders of record as of July 10.
Oracle usually discusses its forward outlook on its earnings call, which is scheduled for 5 p.m. ET.
ORCL Price Action:&nbsp;<a href="https://www.benzinga.com/quote/ORCL" target="_blank" rel="noreferrer noopener">Oracle shares</a>&nbsp;were up 6.99% in Wednesday&#8217;s after-hours session, trading at $188.36 at the time of publication, according to&nbsp;<a href="http://pro.benzinga.com/" target="_blank" rel="noreferrer noopener">Benzinga Pro</a>.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/25/06/45882971/wall-street-eyes-record-highs-as-trump-seals-china-deal-soft-inflation-eases-tariff-jitters">Wall Street Eyes Record Highs As Trump Seals China Deal, Soft Inflation Eases Tariff Jitters</a></li>
<li><a href="https://www.benzinga.com/trading-ideas/previews/25/06/45891931/adobe-q2-earnings-preview-expert-says-guidance-ai-progress-important-after-being-nothing-but-a-heartache-for-investors">Adobe Q2 Earnings Preview: Expert Says Guidance, AI Progress Important After Being &#8216;Nothing But A Heartache For Investors&#8217;</a></li>
</ul>
Photo: <a href="https://www.shutterstock.com/g/jetcityimage">Jonathan Weiss</a>/Shutterstock.

Earnings

Guidance

Oracle Q4 Earnings: Revenue, EPS Beat Estimates, Cloud Infrastructure Growth Expected To Accelerate With Demand 'Skyrocketing'

<a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4447547-1&amp;h=1502065418&amp;u=http%3A%2F%2Fwww.semprainfrastructure.com%2F&amp;a=Sempra+Infrastructure">Sempra Infrastructure</a>, a subsidiary of <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4447547-1&amp;h=2584592947&amp;u=http%3A%2F%2Fwww.sempra.com%2F&amp;a=Sempra">Sempra</a>&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SRE#NYSE">SRE</a>), today announced it has executed a non-binding heads of agreement (HOA) with JERA Co. Inc (JERA) for a 20-year sale and purchase agreement for liquefied natural gas (LNG) offtake of 1.5 million tonnes per annum (Mtpa) on a free on board basis from the Port Arthur LNG Phase 2 development project in Jefferson County, Texas.

Contracts

Sempra Infrastructure Signs Non-Binding Agreement With JERA For 20-Year LNG Offtake From Port Arthur Phase 2

Perpetua Resources Reveals $300M Bought Deal Financing And $100M Private Placement As Part Of Comprehensive Financing Package For Stibnite Gold Project

Perpetua Resources Files For Offering Of Common Shares; Size Not Disclosed

Press Releases

Achievements and Progress Heading into 2025 for Oncology Treatments and Therapies Fuel an Optimistic Outlook

Cardiff Oncology to Report Fourth Quarter 2024 Results and Provide Business Update

Cardiff Oncology to Present at Upcoming Investor Conferences

Cardiff Oncology Reports Fourth Quarter and Full Year 2024 Results and Provides Business Update

Small Cap

Opinion

Why the Global Cancer Market Could Surpass $900 Billion--And the Stocks Leading the Charge

Cardiff Oncology Announces Completion of Enrollment in Phase 2 CRDF-004 Trial Evaluating Onvansertib for the Treatment of First-line RAS-mutated Metastatic Colorectal Cancer

Cardiff Oncology Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Legal

Cardiff Oncology Announces a Second Patent for the Treatment of mCRC for Bev-Naïve Patients

Cardiff Oncology Reports First Quarter 2025 Results and Provides Business Update

Cardiff Oncology Announces Positive Data from Investigator-Initiated Trial of Onvansertib in Combination with Paclitaxel in Metastatic Triple-Negative Breast Cancer Presented at ASCO 2025

Comments

Cardiff Oncology

Noticias

Últimas noticias sobre Cardiff Oncology (NASDAQ:CRDF) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL